Journal
BMC CANCER
Volume 22, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12885-021-09064-0
Keywords
Bladder cancer; Glycolysis; Cholesterol synthesis; Metabolic subtypes; Immune microenvironment
Categories
Funding
- National Natural Science Foundation of China [81802551, 81900688, 81800590]
- Chinese Postdoctoral Science Foundation [2020 M672593]
- Medical Research Foundation of Guangdong Province [B2020011, A2019473]
- Natural Science Foundation of Guangdong Province [2016A030307033, 2019A1515011107]
- Guangdong Provincial Joint Fund Youth Project [2020A1515110117]
- Science and Technology Foundation of Qingyuan City [2020KJJH009]
- Medical Research Foundation of Qingyuan People's Hospital [20190206, 20190205]
Ask authors/readers for more resources
In this study, bladder cancer patients were classified into 4 metabolic subtypes based on the expression levels of glycolytic and cholesterogenic genes. The study revealed that the mixed subtype was associated with poorer prognosis and higher frequency of gene deletion. Furthermore, distinct characteristics were observed in tumor microenvironment and immune cell infiltration patterns among different metabolic subtypes. These findings may provide new insights for personalized treatment strategies targeting metabolic vulnerabilities in bladder cancer.
Background Oncogenic metabolic reprogramming contributes to tumor growth and immune evasion. The intertumoral metabolic heterogeneity and interaction of distinct metabolic pathways may determine patient outcomes. In this study, we aim to determine the clinical and immunological significance of metabolic subtypes according to the expression levels of genes related to glycolysis and cholesterol-synthesis in bladder cancer (BCa). Methods Based on the median expression levels of glycolytic and cholesterogenic genes, patients were stratified into 4 subtypes (mixed, cholesterogenic, glycolytic, and quiescent) in an integrated cohort including TCGA, GSE13507, and IMvigor210. Clinical, genomic, transcriptomic, and tumor microenvironment characteristics were compared between the 4 subtypes. Results The 4 metabolic subtypes exhibited distinct clinical, molecular, and genomic patterns. Compared to quiescent subtype, mixed subtype was more likely to be basal tumors and was significantly associated with poorer prognosis even after controlling for age, gender, histological grade, clinical stage, and molecular phenotypes. Additionally, mixed tumors harbored a higher frequency of RB1 and LRP1B copy number deletion compared to quiescent tumors (25.7% vs. 12.7 and 27.9% vs. 10.2%, respectively, both adjusted P value< 0.05). Furthermore, aberrant PIK3CA expression level was significantly correlated with those of glycolytic and cholesterogenic genes. The quiescent subtype was associated with lower stemness indices and lower signature scores for gene sets involved in genomic instability, including DNA replication, DNA damage repair, mismatch repair, and homologous recombination genes. Moreover, quiescent tumors exhibited lower expression levels of pyruvate dehydrogenase kinases 1-3 (PDK1-3) than the other subtypes. In addition, distinct immune cell infiltration patterns were observed across the 4 metabolic subtypes, with greater infiltration of M0/M2 macrophages observed in glycolytic and mixed subtypes. However, no significant difference in immunotherapy response was observed across the 4 metabolic subtypes. Conclusion This study proposed a new metabolic subtyping method for BCa based on genes involved in glycolysis and cholesterol synthesis pathways. Our findings may provide novel insight for the development of personalized subtype-specific treatment strategies targeting metabolic vulnerabilities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available